Cost-utility analysis of panitumumab use compared with cetuximab and bevacizumab for the first-line therapy of wild-type RAS metastatic colorectal cancer in the Peruvian health system.

被引：0
|
作者：
Milton, Valderrama
Apolaya-Segura, Moises
Montenegro, Paola Catherine
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e15171
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15171
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
    Graham, Christopher N.
    Hechmati, Guy
    Fakih, Marwan G.
    Knox, Hediyyih N.
    Maglinte, Gregory A.
    Hjelmgren, Jonas
    Barber, Beth
    Schwartzberg, Lee S.
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (08) : 619 - 628
  • [2] COST-MINIMIZATION ANALYSIS OF BEVACIZUMAB COMPARED TO CETUXIMAB AND PANITUMUMAB IN FIRST-LINE TREATMENT OF KRAS WILD-TYPE METASTATIC COLORECTAL CANCER IN FRANCE
    Gherardi, A.
    Masia, C.
    Plommet, N.
    VALUE IN HEALTH, 2016, 19 (07) : A738 - A738
  • [3] COST-MINIMIZATION ANALYSIS OF PANITUMUMAB COMPARED WITH CETUXIMAB IN THE FIRST-LINE TREATMENT OF WILD-TYPE RAS METASTATIC COLORECTAL CANCER PATIENTS IN BRAZIL
    dos Santos, R. F.
    Riveros, B. S.
    Nita, M. E.
    Pedro, G. O.
    VALUE IN HEALTH, 2016, 19 (07) : A738 - A739
  • [4] Cost-Effectiveness Analysis of Panitumumab Compared with Bevacizumab for First-Line Treatment of Patients with Wild-Type RAS Metastatic Colorectal Cancer in Germany
    Frank, M.
    Lange, A.
    Michailov, G.
    Lebioda, A.
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2016, 21 (04): : 203 - 209
  • [5] Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England
    Irina A. Tikhonova
    Nicola Huxley
    Tristan Snowsill
    Louise Crathorne
    Jo Varley-Campbell
    Mark Napier
    Martin Hoyle
    PharmacoEconomics, 2018, 36 : 837 - 851
  • [6] Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England
    Tikhonova, Irina A.
    Huxley, Nicola
    Snowsill, Tristan
    Crathorne, Louise
    Varley-Campbell, Jo
    Napier, Mark
    Hoyle, Martin
    PHARMACOECONOMICS, 2018, 36 (07) : 837 - 851
  • [7] A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US
    Graham, Christopher N.
    Christodoulopoulou, Alexandra
    Knox, Hediyyih N.
    Sabatelli, Lorenzo
    Hechmati, Guy
    Garawin, Tamer
    Strickler, John H.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (11) : 1075 - 1083
  • [8] First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Bobo Zheng
    Xin Wang
    Mingtian Wei
    Quan Wang
    Jiang Li
    Liang Bi
    Xiangbing Deng
    Ziqiang Wang
    BMC Cancer, 19
  • [9] First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Zheng, Bobo
    Wang, Xin
    Wei, Mingtian
    Wang, Quan
    Li, Jiang
    Bi, Liang
    Deng, Xiangbing
    Wang, Ziqiang
    BMC CANCER, 2019, 19 (1)
  • [10] CANADIAN ECONOMIC ANALYSIS OF BEVACIZUMAB, CETUXIMAB, AND PANITUMUMAB IN THE FIRST LINE TREATMENT OF KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (MCRC)
    Lawrence, D.
    Maschio, M.
    Yunger, S.
    Easaw, J.
    Aucoin, N.
    Weinstein, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 202 - 202
12345